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Abstract
Background: HPV DNA Array is an E1-targeting PCR genotyping test, with capability of distinguishing 18 high-risk
(16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) and 11 low-risk HPV types (6, 11, 40, 42, 44, 54, 67,
69, 70, 85, 97). HPV DNA Array uses multiplex PCR for E1-gene sequence amplification. The amplicons are detected
and genotyped by reverse hybridization to immobilized DNA probes spotted as triplets in single 96 well-plate wells
and read by AID ELISPOT reader.
Methods: Aim of the study was to evaluate the clinical performance of the assay against internationally accepted
and FDA approved Cobas 4800 HPV test (Roche Diagnostics). Study population comprised of 500 cervical samples.
Results: HPV DNA Array demonstrated a very high sensitivity of 100% for CIN2+ and 100% for CIN3+ detection,
same as Cobas 4800. HPV DNA Array showed greater sensitivity for CIN2+ detection than cytology (100% vs. 13.6%).
The agreement to Cobas 4800 for HPV detection, irrespective of type, was 81.4% with κ = 0.613. The agreement for
HPV 16 was 92.8% (κ = 0.929), and for HPV 18 54.2% (κ = 0.681).
Conclusion: HPV DNA Array demonstrated good clinical performance for detection of high-grade lesions, and may
be considered for usage in a screening setting.
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Background
Cervical cancer, caused by persistent HPV infection [1],
is an easily preventable disease. With the introduction of
mass cervical cancer screening, a significant 75% decline
in cancer incidence has been observed in developed
countries, achieved through regular cytological screening
[2, 3]. However, cytology is a method hard to implement
in developing countries and has a variable sensitivity for
disease detection (44–78%) [4]. The recent advancement
of detection methods, and the causal link between HPV
and cervical cancer, has led to a change in paradigm.
HPV testing advanced from usage as a triaging method
to a method for primary cervical cancer screening,
approved by WHO [5] and FDA. In 2014, the Cobas
4800 HPV test (Roche Diagnostics) was approved by
FDA for primary cervical cancer screening in the USA
[6]. The following year, the American Society for
Colposcopy and Cervical Pathology included the HPV
genotyping tests as primary tests (without cytology) for
cervical cancer screening in its guidelines [7].
There is evidence that HPV-based screening is more
sensitive in detecting high grade lesions [8–10], and is
clinically more informative. HPV-based screening could
give prognostic information e.g. positivity for high-risk
(HR) HPV at 6 months after lesion treatment, can
predict lesion recurrence [11]. Also, women with HPV
persistence of more than 7 years have a higher risk of
lesion development and progression to invasive cancer
[12]. Additionally HPV genotyping could provide more
clinical information as not all HPV types have the same
risk for cancer development, e.g. HPV 16 more than
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other HR-HPV types; multiple HPV infections more
than single infections [13, 14].
The main objective of this study was to report on
clinical performance of HPV DNA Array in detection of
cervical lesions and to compare its analytical capability
to Cobas 4800 HPV test on a study population com-
prised of 500 cervical samples.
HPV DNA Array is a full HPV genotyping assay, newly
developed by AID Diagnostika GmbH (Strassberg,
Germany), which is capable of genotyping separately for
29 HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53,
56, 58, 59, 66, 68, 73, 82, and 6, 11, 40, 42, 44, 54, 67, 69,
70, 85, 97).
Materials and methods
Study population and sample preparation
Five hundred consecutive taken samples of approx. 4000
cervical scrapings collected for the “HEllenic Real life
Multicentric cErvical Screening” (HERMES), a study that
compared cytology and HPV-based screening [15] were
selected. Samples were collected from women undergo-
ing routine cervical screening at 9 different outpatient
Clinics in Greece (Athens, Thessaloniki, Larisa, Patras
and Alexandropoulis). Cervical scrapings were taken
with Cervex Brush (Rovers Medical Devices, Oss,
Netherlands) and rinsed in ThinPrep. One part of the
sample was used for cytology, one part for HPV test-
ing with Cobas HPV test, and the leftover volume of
500 samples was stored at + 4 °C and sent to Charité-
Universitätsmedizin Berlin, Germany. One sample was
not included in the shipment, hence, 499 samples
were analyzed.
For this study, 2 ml of each sample was used for DNA
extraction by QIAamp DNA Mini Kit, in accordance
with manufacturer’s instructions. Nucleic acid was eluted
in a final volume of 160 μl.
HPV DNA Array
HPV DNA Array detects multiplex PCR amplified E1-
gene sequences by a reverse hybridization reaction in a
96 well microtiter plate. Oligonucleotide probes, specific
for each HPV type, are spotted on a bottom of each well.
After hybridization, colored spots were evaluated by ELI-
Spot reader and reading software AiDot (AID Diagnostika
GmbH, Strassberg, Germany). HPV DNA Array is capable
of genotyping 18 high-risk (16, 18, 26, 31, 33, 35, 39, 45,
51, 52, 53, 56, 58, 59, 66, 68, 73, 82) and 11 low-risk HPV
types (6, 11, 40, 42, 44, 54, 67, 69, 70, 85, 97).
The person performing the HPV DNA Array testing
was blinded to the Cobas HPV results, cytology and
histology status of the samples collected.
The assays use different target sequences. While Cobas
4800 relies on the more conserved genomic region of L1
the HPV array detects sequences of the E1 that is a
larger and more diverse and has more opportunities for
type-specific probe sequences and a wider inclusion of
genotypes in a multiplexed PCR assay.
Cobas 4800 HPV test
The Cobas 4800 HPV is a L1-based PCR test with cap-
ability of separately genotyping HPV 16 and − 18, and
grouping other 12 HR-HPV types (31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66 and 68) in a single signal.
HPV testing was performed as described by Castle et
al. [16] at the Laboratory of Microbiology, Democritus
University of Thrace, Alexandroupolis, Greece. The
performer was blinded to cytology and histology results.
Cytology
The cytological smear examination was performed at the
corresponding pathology laboratory of the participating
hospital where sample was taken. Bethesda 2001
cytology classification guideline was followed [17]. The
cytologists were blinded to the HPV DNA test results.
Sample analysis
Agreement, sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) were
used as main outcomes. Cohen’s Kappa values deter-
mined the agreement between the assays and were inter-
preted as follows [18]: poor (< 0.20), fair (0.21–0.40),
moderate (0.41–0.60), good (0.61–0.80), very good
(0.81–1.00). The values of McNemar’s test were used to
evaluate if significant discrepancies exist.
Cobas 4800 HPV test gives information on HPV
positivity by genotyping separately HPV 16 and HPV 18,
and reporting the results for 12 other HR-HPV types in
a pool (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68),
hence, the HPV DNA Array detected HPV types were
grouped accordingly for comparative analytical purposes.
Only 14 HPV types covered by both assays were
included in the analysis (HPV 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, and 68).
Statistical analysis was performed with IBM SPSS
Statistics for Windows (Version 21.0. IBM Corp.
Armonk, NY) and MedCalc 15.8 (MedCalc Software,
Ostend, Belgium).
Results
Characteristics of the study population
Four hundred ninety-nine samples were received from
the HERMES study from women aged 19 to 66 years,
with an average age of 33 years. 217 women were
younger than 30 years, 276 were 30 years or older, and
for 6 samples, age information was unavailable. Ninety-
five samples were HPV negative by Cobas HPV test, and
404 were HPV positive. HPV 16 was detected in 97
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samples, HPV 18 in 48 samples, and 321 samples were
positive for 12 other HR-HPV types.
Cytology result was obtained from 360 women: 274
had normal cytology, 43 had ASCUS, 35 LGSIL and 8
had HGSIL. Biopsy was taken for 74 women: 23 had
normal histology, 29 had CIN1, 17 had CIN2 and 5 had
CIN3 lesions. No cases of cervical cancer were reported
in this population.
HPV DNA Array results and sample re-testing
All 499 samples were tested with HPV DNA Array. An
HPV negative result was found in 146 samples, and 353
samples were HPV positive.
A discrepancy to Cobas was observed in 90 samples
(HPV DNA Array+/Cobas-, HPV DNA Array−/Cobas+
or both assays positive with different HPV types). To ex-
clude test execution mistake, the 90 samples were re-
tested with HPV DNA Array, along with 10 concordant
samples, as control. All control samples had the same
concordant results. In 82 samples, the result stayed the
same, still discordant to Cobas, and in 8 samples, the re-
sult changed. To confirm which result was true, a third
testing was performed, and only HPV types found in 2
or more tests were counted as truly positive. Four sam-
ples were initially HPV negative and now became HPV
positive, matching the Cobas result; three samples were
LR-HPV positive and now showed a co-infection with
HR-HPV, and one sample was initially HPV positive for
HPV 16, but after re-testing it was twice HPV negative.
In summary, after re-evaluation, HPV DNA Array
deemed 143 samples to be HPV negative and 356 sam-
ples, as HPV positive, among which 25 samples only for
types not detected by Cobas, e.g. HPV 42, − 53, − 54,
and − 67, hence these samples were additionally placed
in the HPV negative group for analysis.
We present the analysis on the re-evaluated results.
CIN2+ lesion detection
HPV DNA Array showed a sensitivity for detecting
CIN2+ lesions of 100% (95% CI, 84.6–100%), with a spe-
cificity of 9.43% (95% CI, 3.1 to 20.7%), PPV 31.43%
(95% CI, 20.8 to 43.6%), and NPV 100% (95% CI, 47.8 to
100%) (Table 1). Similarly we observed a sensitivity of
100% for CIN3+ detection with all 5 lesions detected by
HPV DNA Array.
Cobas test had a sensitivity for detection of CIN2+
lesions of 100% (95% CI, 84.6–100%), with a specificity
of 0% (95% CI, 0 to 6.7%).
A difference between the assays was observed only for
detection of low-grade lesions approx. 80% vs. 100% of
Cobas, leading to a lower specificity of Cobas test.
When compared against cytology (Table 1), HPV DNA
Array demonstrated a much better sensitivity for CIN2+
detection, 100% of HPV DNA Array vs. 13.6% of
cytology. Only 4 of 22 CIN2+ lesions were classified as
HGSIL. Conversely, specificity was much higher with
cytology 84.9% (95% CI, 72.4 to 93.2%) than with HPV
DNA Array 9.43% (95% CI, 3.1 to 20.7%).
HPV detection
HPV DNA Array was positive in 66.3% (331/499) cases,
as compared with 81% (404/499) of Cobas HPV test
(Table 2).
The agreement between the assays was 81.4% (95% CI,
80.8 to 87.5%) with κappa 0.613 (95% CI, 53.9 to 68.7%).
The results were stratified according to age; sensitivity,
agreement for HPV detection and specificity within < 30
group were 86.2% (95% CI, 80.5 to 90.8%), 0.618 (95%
CI, 49.1 to 74.5%), 100% (95% CI, 87.6 to 100%), and
within ≥30 group 77.4% (95% CI, 84.6 to 100%), 0.593
(95% CI, 49.9 to 68.8%) and 96.87% (95% CI, 89.2 to
99.6%), respectively. Values of the McNemar’s test deemed
the differences statistically significant (p = 0.000).
Further on, when focusing on agreement among
CIN2+/HGSIL lesions, an agreement of 100% was
observed.
HPV partial genotyping
Cobas test genotypes HPV 16 and − 18 separately, and
groups the results of 12 HR-HPV types in a pool (31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), hence, the
HPV DNA Array results were adjusted accordingly.
HPV 16 was detected in 90 samples by HPV DNA
Array, as compared with 97 found by Cobas (Table 3),
leading to a sensitivity of 92.8% (95% CI, 85.7 to 97%)
and kappa agreement of 0.929 (95% CI, 88.7 to 97%),
with specificity 99.0% (95% CI, 97.5 to 99.7%), and PPV
and NPV 95.74% (95% CI, 89.5 to 98.8%) and 98.27%
(95% CI, 96.5 to 99.3%). McNemar’s test value was
greater than 0.05.
HPV DNA Array detected HPV 18 in 26 samples vs.
48 found by Cobas, demonstrating a sensitivity of 54.2%
(95% CI, 39.2 to 68.6%) with moderate agreement (κ =
0.681, 0.558 to 0.805), specificity of 100% (95% CI, 99.2
to 100%) and PPV and NPV of 100% (95% CI, 86.% to
100) and 95.3% (95% CI, 93 to 97%). McNeimar’s test
value was less than 0.05.
Twenty-two HPV 18 Cobas positive samples were not
detected by HPV DNA Array. Thirteen were single in-
fections by Cobas, and 9 samples were co-infections
with HPV 16 and/or other HR-HPV, all of which were
detected by HPV DNA Array and only HPV 18 was
missed in the multiple infections.
Histology was available for 6 samples of 22 missed.
We observed that only one sample had a histologically
confirmed high-grade lesion (CIN2) and was a Cobas de-
tected multiple infection. In that case, HPV DNA Array
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failed to detect HPV 18, but other HR-HPV types
present in the infection were found.
Sensitivity for detecting 12 other HR-HPV types was
75.4% (95% CI, 70.3 to 80%) with 242 samples detected
as compared with 321 by Cobas. Kappa showed good
agreement of 0.677 (95% CI, 61.6 to 73.9%). Specificity,
PPV and NPV were 98.88% (95% CI, 96 to 99.9%),
99.18% (95% CI, 97 to 99.9%) and 69.02% (95% CI, 62.9
to 74.6%). The difference was graded statistically signifi-
cant (McNemar’s p < 0.05).
HPV DNA Array was negative for other HR-types in
75 cases, whereas Cobas was positive. Sixty-five were
single infections, and ten samples were co-infections
with HPV 16. In all cases HPV DNA Array detected
HPV 16. Histology was available for only 7 of the 75
samples. Six samples had a low grade lesion (<CIN2),
and in one case a high-grade lesion (CIN3) was
confirmed. In that case Cobas showed a co-infection of
12 other HR types with HPV 16. HPV DNA Array did
detect HPV 16, missing to detect other HR-HPV types.
Discussion
Main aim of this study was to investigate the HPV DNA
Array’s ability to detect high-grade lesions by comparing
its performance with Cobas HPV test, a validated and
FDA approved assay for primary screening, and with
cytology, an established method for cervical cancer
screening.
HPV DNA Array was found to be a simple and short
assay (assay execution was in total four hours, with a
hands-on time of approx. two hours). It included a
reverse hybridization step, and an ELISA-like staining
for assay development. The readout was automated with
the ELISPOT reader and an AiDot software that evalu-
ated the full 96 well plate in approx. three minutes. HPV
DNA Array is a time efficient assay that allows high
throughput, which could be of great benefit for mass
screening. Additionally, the HPV DNA Array could be
used for epidemiology of HPV, as it fully genotypes and
includes most prevalent LR-HPV types (Manuscript in
preparation).
In this study, HPV DNA Array demonstrated a very
high clinical performance with a sensitivity for detecting
CIN2+/3+ lesions of 100%, identical to the clinical sensi-
tivity of Cobas HPV test, and higher than cytology
(13.6%) in this population. The Cobas HPV test is well
investigated and its performance is well documented in
the literature. Other researchers reported a similar per-
formance [19, 20]. However, surprisingly, a low sensitiv-
ity of cytology, 13.6%, with only 3 of 22 CIN2+ lesions
classified as HGSIL, was found. Although it has been
documented that HPV assays are more sensitive for
Table 2 HPV detection between HPV DNA Array and Cobas, stratified by age, histology, and cytology
Cobas
HPV DNA Array Positive Negative Agreement Kappa Interpretationa McNemar’s p
Overall population (499) Positive 329 2 81.4% 0.613 good 0.000
Negative 75 93
< 30 (217)b Positive 163 0 86.2% 0.618 good 0.000
Negative 26 28
≥30 (276) b Positive 164 2 77.4% 0.593 moderate 0.000
Negative 48 62
CIN2+ (22) Positive 22 0 100%
Negative 0 0
HGSIL (8) Positive 8 0 100%
Negative 0 0
aInterpretation values: poor (< 0.20), fair (0.21–0.40), moderate (0.41–0.60), good (0.61–0.80), very good (0.81–1.00)
b6 samples, for which the age information was unavailable, were excluded from the analysis
Table 1 HPV detection stratified to histology and cytology
HPV DNA Array Cobas Cytology
Histology Total HPV+ % HPV+ % Normal ASCUS LGSIL HGSIL
Normal 23 18 78.2% 23 100% 17 3 2 1
CIN1 29 24 82.7% 29 100% 19 4 6 0
CIN2 17 17 100% 17 100% 11 0 3 3
CIN3 5 5 100% 5 100% 3 1 1 0
CIN2+ 22 22 100% 22 100% 13.6%
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disease detection in comparison with cytology [21], such
difference was not expected. Koliopoulos et al. [21] re-
ported a sensitivity of cytology of approx. 60%, however,
in this study, it was only 13.6%.
Looking at agreement for HPV detection, irrespective
of type, HPV DNA Array showed a good agreement of
81.4% (k = 0.613) as compared with Cobas. This
difference was rated statistically significant by McNe-
mar’s test (p < 0.05), nonetheless, since all CIN2+ cases
were detected, the difference had no clinical meaning.
Analyzing the agreement for specific HPV types, a
high sensitivity for detection of HPV 16 was observed
(>90%, k = 0.929), which is the most common cancer
causing genotype [22]. A lower sensitivity for HPV 18
detection (54.2%, κ = 0.681, p < 0.05), and for detection
of other 12 HR-types (75.4%, κ = 0.677, p < 0.05) was
found. This is an intrinsic difference due to the different
target, primers and probes between the two assay sys-
tems compared and the HPV types in the HPV array. It,
however, did not reduce the clinical sensitivity of the
assay as compared to Cobas 4800. It was observed that
although the HPV 18 and/or other HR types were
missed, other HPV types present in the infection were
detected. Unfortunately, histology information was not
available for all of the HPV DNA Array missed cases,
however, HPV DNA Array did detect the high risk
lesions, therefore, the analytical differences had little
clinical bearing. One could suspect that the HPV types
missed were not drivers of the infection, but little infor-
mation is available in the literature.
The tendency of HPV DNA Array to have a lower
agreement for HPV detection, but a very good agreement
for detection of cervical intraepithelial neoplasia to the
reference assays, could be explained by the higher number
of viral copies in such lesions. Cervical intraepithelial neo-
plasia tends to have larger viral amounts and is, therefore,
easier to detect [23]. It is then important that HPV assays
which are meant to be used as screening tests have the
right balance of clinical sensitivity and specificity [23].
We believe that the performance differences between
HPV DNA Array and Cobas could occur due to
differences in assay design (manual vs. automated DNA
isolation), genotype spectrum detected, the target HPV
gene (HPV DNA Array-E1, Cobas HPV test-L1 gene),
and genotyping ability (full vs. partial genotyping).
Evidently, when comparing HPV assays, an ideal high
agreement is difficult to reach, as shown by Rebolj et al.
[24]. In their paper on disagreement between HPV
screening tests, they reported a 41% concordance for
HPV positivity, irrespective of type, among 4 different
fully validated HPV assays (Hybrid Capture 2, Cobas,
CLART and APTIMA). The agreement among assays
was even lower in the 30–65-year-old screening popula-
tion, 29%. When focusing specifically on the Cobas test,
which we also used in our study, it was observed that the
agreement for HPV positivity, irrespective of type, to
HC2, CLART, and APTIMA, varied between 50 and 70%.
Although, Rebolj et al. did not analyze genotype-specific
agreement, as in this study, and did not include HPV
DNA Array in their comparison, the agreement of HPV
DNA Array with Cobas of > 80%, underlines the good per-
formance of HPV DNA Array for HPV detection.
Samples used in this study were received from HER-
MES study panel for validation purposes and do not rep-
resent a screening population. This explains the higher
number of HPV positive and lesion positive samples
than expected, approx. 80% within this study vs. approx.
10% within screening studies [20]. Within the HERMES
study, 12.7% of samples were HPV positive [15], which
is in concordance with other publications [20]. Further-
more, the HPV−/disease- population was underrepre-
sented, leading to a lower specificity, due to a high
number of HPV positive, but histologically normal sam-
ples. Therefore, the validation criteria set by Meijer et al.
[23] could not be fulfilled, due to lack of samples from
women undergoing regular cervical cancer screening.
However, despite the sample background, the sensitivity
of HPV DNA Array for detection of CIN2+ in women
30 years of age and older was > 90% of the reference
assay, as required by Meijer et al. [23]. Further studies
that will investigate if similar results can be reproduced
in a screening population are justified.
The main limitation of this study was re-testing of the
discordant samples with HPV DNA Array and the
change of HPV results in 8 out of 90 re-tested samples.
This change could occur during PCR and/or
hybridization, as a pipetting error, reading error or con-
tamination. Such re-testing was included in the analysis
for validation purposes, but would not be feasible during
routine diagnostics.
Table 3 HPV genotype detection of HPV DNA Array in comparison with Cobas
Cobas HPV DNA Array Agreement Kappa Interpretationa McNemar’s p
HPV 16 97 90 92.8% 0.929 very good 0.549
HPV 18 48 26 54.2% 0.681 good 0.000
12 other HR-HPVb 321 242 75.4% 0.677 good 0.000
a Interpretation values: poor (< 0.20), fair (0.21–0.40), moderate (0.41–0.60), good (0.61–0.80), very good (0.81–1.00);
b HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
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Conclusion
This validation study has demonstrated the high
potential of HPV DNA Array for detection of CIN2+/3+
lesions. HPV DNA Array has shown a very high clinical
sensitivity of 100% for CIN2+ and 100% for CIN3+
detection, same as Cobas 4800; despite the analytical
difference in detection of HPV 16 and 18 between the
assays. Future studies are warranted to complete the
validation and investigate the performance of HPV DNA
Array in population-based screening and potentially in
low resource settings.
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